Although not yet popular, lab-grown meat is fast becoming a real alternative to its farm-grown counterpart as billionaire entrepreneurs and industry heavyweights invest into start-ups from across the nascent field of “cellular agriculture”. Produced via induced pluripotent stem cells (iPSCs) derived from cows, pigs, fish, or sheep, the emerging clean meat industry has the potential to transform the global food market and create a new trillion dollar industry in the process. [Read more…]
MSCs as an Appealing Raw Material for Use in Regenerative Medicine
Mesenchymal stem cells (MSCs) are a type of non-controversial, adult stem cell that prefers to differentiate into the specialized cells found in skeletal tissues, such as cartilage cells (chondrocytes), bone cells (osteoblasts), and fat cells (adipocytes). In contrast, stem cells derived from embryos are capable of developing into all the different types of cells found in our body, which makes them more versatile than MSCs, but also more controversial. Induced pluripotent stem cells also exhibit greater pluripotency, but as modified cells, they come with a greater set of regulatory challenges. [Read more…]
World first: TreeFrog Therapeutics announces the production of a single batch of 15 billion iPS cells in a 10L bioreactor with exponential amplification of 276-fold per week
Biomimetic 3D cell culture technology unlocks the manufacturing bottleneck of stem-cell derived cell therapies through exponential hiPSC growth in large-scale bioreactors, with best-in-class cell quality.
Bordeaux, France – April 13th, 2021. French cell therapy company TreeFrog Therapeutics announces unprecedented exponential growth of human induced pluripotent stem cells (hiPSC) in a 10L bioreactor[1]. Using proprietary C-StemTM technology, TreeFrog Therapeutics amplified 50 million hiPSC into a single batch of 15 billion cells in 6.5 days, and company reports exceptional cell quality. Data will be presented at the International Society for Stem Cell Research (ISSCR) Virtual Meeting, taking place June 21 – 26, 2021. [Read more…]
Shoreline Biosciences Raises $43M to Advance iPSC-derived Cellular Immunotherapies
Shoreline Biosciences, a California-based start-up specializing in iPSC-derived cellular immunotherapies for cancer and other serious diseases, announced it has completed an impressive $43M funding round. Founded in 2020 in La Jolla, CA, the company is developing a pipeline of induced pluripotent stem cell (iPSC) derived NK cell and macrophage cell therapy product candidates. The company joins an impressive list of pioneers who are now forging the path toward iPSC-derived cell therapeutics. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2021
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
